Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 9,165 Shares of Stock

Key Points

• Insider Krishnaswamy Yeleswaram sold a total of 20,225 shares of Rapport between April 8–14 (including 9,165 on April 13) for roughly $708,370, and still holds 276,851 shares after the trades.
• RAPP shares climbed about 4.3% to $36.15 on Tuesday on above-average volume, with a market cap near $1.73 billion and the stock trading well above its 50- and 200-day moving averages.
• Analysts remain largely positive, with a consensus "Buy" rating and an average price target of $53.83, while several firms have recently raised targets (e.g., Raymond James $66, Wells Fargo $46) despite a recent quarterly EPS miss.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 9,165 shares of the business's stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $34.97, for a total value of $320,500.05. Following the sale, the insider owned 276,851 shares in the company, valued at $9,681,479.47. The trade was a 3.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Krishnaswamy Yeleswaram also recently made the following trade(s):

• On Tuesday, April 14th, Krishnaswamy Yeleswaram sold 10,200 shares of Rapport Therapeutics stock. The stock was sold at an average price of $35.08, for a total value of $357,816.00.
• On Friday, April 10th, Krishnaswamy Yeleswaram sold 500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.98, for a total value of $17,490.00.
• On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.90, for a total value of $12,564.00.

Rapport Therapeutics Trading Up 4.3%

Shares of RAPP stock traded up $1.50 during trading hours on Tuesday, reaching $36.15. 496,199 shares of the company's stock were exchanged, compared to its average volume of 328,964. Rapport Therapeutics, Inc. has a 1 year low of $7.73 and a 1 year high of $42.27. The stock has a market cap of $1.73 billion, a PE ratio of -12.64 and a beta of 1.09. The stock's fifty day moving average price is $29.41 and its two-hundred day moving average price is $28.29.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.07). On average, equities analysts expect that Rapport Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on RAPP shares. Raymond James Financial started coverage on Rapport Therapeutics in a research note on Friday. They set a "strong-buy" rating and a $66.00 price target on the stock. The Goldman Sachs Group restated a "buy" rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Wells Fargo & Company upped their target price on Rapport Therapeutics from $43.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, March 11th. BTIG Research upped their target price on Rapport Therapeutics to $47.00 and gave the company a "buy" rating in a research report on Monday, March 9th. Finally, Citigroup reiterated a "market outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $53.83.

Institutional Investors Weigh In On Rapport Therapeutics

A number of large investors have recently bought and sold shares of the company. Strs Ohio boosted its position in Rapport Therapeutics by 23.5% in the third quarter. Strs Ohio now owns 2,100 shares of the company's stock valued at $62,000 after buying an additional 400 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Rapport Therapeutics by 56.9% in the fourth quarter. Russell Investments Group Ltd. now owns 2,282 shares of the company's stock valued at $69,000 after buying an additional 828 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Rapport Therapeutics by 64.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock valued at $70,000 after buying an additional 905 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Rapport Therapeutics in the fourth quarter valued at approximately $37,000. Finally, Creative Planning boosted its position in Rapport Therapeutics by 12.8% in the third quarter. Creative Planning now owns 11,959 shares of the company's stock valued at $355,000 after buying an additional 1,357 shares during the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.